06.09.2021

Geistlich Pharma secures rights to market world’s first artificial meniscus

 

Wolhusen LU/Schlieren ZH - Geistlich Pharma AG has entered into a partnership with the US firm Active Implants LLC. With this agreement, Geistlich is now in a position to exclusively market the world’s first artificial meniscus prosthesis in Switzerland.

 

The world’s first artificial meniscus is now available in Switzerland after Geistlich Pharma AG agreed a partnership with Active Implants LLC. As part of the Geistlich Group based in Schlieren in the canton of Zurich, the former has now secured exclusive commercialization rights in Switzerland for the meniscus prosthesis that goes by the name of  NUsurface. The product is already available on the Belgian, German, Israeli, Italian and UK markets.

 

According to a press release issued by Active Implants, NUsurface is the first artificial meniscus to be marketed across Europe. The meniscus replacement is manufactured using medical polymer. This mimics the function of the natural meniscus by acting as a shock absorber, thereby helping to evenly distribute weight transmitted across the knee joint. As a result, patients are offered a safe and effective surgical alternative to knee replacement operations.

 

“With Geistlich Pharma’s focus on knee preservation through the regeneration of bone, cartilage and tissue, we feel confident that our two organizations are aligned in our core values”, comments Ted Davis, CEO of Active Implants, in the press release. He adds: “We look forward to expanding access to the NUsurface through their world-class medical education, training and support”.

 

The collaboration between the two companies started in 2019 with the launch of the MEFISTO project within the framework of the Horizon 2020 program of the European Union (EU). It aims to preserve joints by delaying or avoiding surgical interventions such as knee replacement operations that can ultimately damage the joint.


Geistlich Pharma AG



Back to overview